Are you looking for the best biotech penny stocks to buy right now? Well, in 2021, there are quite a few options for your watchlist. The best way to begin is by narrowing down the list to a handful of companies that could have either short or long-term value. This is best identified by understanding both what compounds or medical devices it has in its pipeline as well as what its financial situation is.
It’s not enough to simply find a biotech penny stock to watch simply because it is trending on Robinhood or on social media. However, creating a list of penny stocks based on the frequency they are mentioned online, can be a valuable strategy. But once this list is compiled, investors should move on to the research stage.
With hundreds of biotech stocks to choose from, it is difficult to land on only a few that could be profitable. With Covid cases increasing again, investors are focusing on companies that could benefit. And, the other effect of the pandemic is that it has increased attention on the biotech industry as a whole. So, considering all of these factors, here are nine biotech penny stocks that should be on your watchlist right now.4 Biotech Penny Stocks to Watch Right Now
- Advaxis Inc. (NASDAQ: ADXS)
- Second Sight Medical Products Inc. (NASDAQ: EYES)
- SenesTech Inc. (NASDAQ: SNES)
- Rigel Pharmaceuticals Inc. (NASDAQ: RIGL)
Up by a solid 34%, or so at midday is ADXS stock. We’ve covered Advaxis Inc. plenty of times in the past few months due to its promising technology and large intraday movement and today is no different. While large gains among penny stocks can occur without any news, ADXS made a big announcement today.
During pre-market, shares of ADXS stock pushed up after an announcement that it has signed into a definitive merger agreement with Biosight Ltd. The combined entity will become Biosight Therapeutics and will work on advancing the current pipeline of products that Biosight holds. Additionally, the company will begin in a very advantageous cash position, holding around $50 million at the time the deal closed.
“After an extensive and thorough review of strategic and potentially transformative options for Advaxis, we are very pleased to announce a proposed merger with Biosight.
We believe the combined company’s strong and diversified oncology pipeline with late-stage and early-stage assets, near-term milestones, seasoned leadership team, and focus on both hematological and solid tumors have the potential to provide transformative benefits to patients while also providing value to our stockholders.”Kenneth A. Berlin, CEO of Advaxis
This is big news and could continue to play out in the coming weeks to months. Considering this, will ADXS stock be on your watchlist in July?Second Sight Medical Products Inc. (NASDAQ: EYES)
At just under $4.50 per share, EYES stock has climbed dramatically in the past few months. Since January, shares of EYES are up by over 150%, there’s plenty of reason for that. Only a week or two ago, Second Sight announced the closing of a sizable public offering. The offering, worth around $57.5 million, includes 1.5 million shares at a price of $5 per share. It states that the proceeds will go toward continued development of its Orion device as well as general corporate purposes.
In May, it stated that it received notice from the NIH for the release of its year there funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis. This is known as the Orion Trial and is funded by a $6.4 million grant over five years from the NIH.
The Orion device is an implanted cortical stimulation product that could effectively provide vision to those without it. This is a major breakthrough and could prove to be a large financial benefit to the company if all goes according to plan. With all of these things in mind, will EYES stock make your watchlist?SenesTech Inc. (NASDAQ: SNES)
Another big gainer of the day is SNES stock, pushing up by around 15% by midday. While no company-specific news was announced today, we can look at some older announcements and what the company does as a whole. SenesTech is a producer of pest control products, such as rodent contraceptives and other rodent management devices. While it isn’t a biotech company in the more traditional sense of the term, it does work in the animal health industry.
The company created the ContraPest product, which is the world’s first and only U.S. EPA registered rodent contraceptive. This can be put to use in a variety of uses including traditional pest management, and new methods in the pest control industry. A few weeks ago, the company announced its first-quarter results for 2021. In the results, the company stated that California is its largest market, accounting for almost a third of its overall revenue. This is due to the state enacting legislation that bans the use of the four most popular rodenticides, paving the way for ContraPest use in the state.
Ken Siegel, CEO of SenesTech, states that “California is a huge market and we expect our growth to continue there and in other markets around the country as the pest control industry and other customers look for new solutions to rat control.” Considering the legislation put in place by California and SNES’s advantageous market position, it could be worth keeping an eye on.Rigel Pharmaceuticals Inc. (NASDAQ: RIGL)
Rigel Pharmaceuticals Inc. is another popular biotech penny stock right now. The main reason for this is its role in producing Covid-19 related compounds. This includes its fostamatinib oral spleen tyrosine kinase inhibitor. Fostamatinib was recently selected by the NIH for a new trial in those hospitalized with Covid-19. This is big news and follows a recently completed study, where it met all of its endpoint safety goals.
“Despite welcome advances in some areas, Covid-19 and its variants will remain a real public health threat for the foreseeable future, particularly for those with pre-existing conditions.
The teams at the NIH and VUMC are ideally positioned to continue to advance clinical efforts for Covid-19 related lung injuries, including the study of fostamatinib’s potential to treat and prevent conditions caused by an overactive immune system in Covid-19 patients.”Raul Rodriguez, CEO of Rigel
While there are plenty of biotech penny stocks to watch right now, only a handful are actively working on Covid related treatments. This puts RIGL stock at the forefront of the pandemic and is one of the main reasons that it has increased substantially in popularity. With all of this in mind, RIGL could be an interesting addition to your biotech penny stocks watchlist.5 More Biotech Penny Stocks to Watch
- Odonate Therapeutics Inc. (NASDAQ: ODT)
- Avinger Inc. (NASDAQ: AVGR)
- Endo International Plc. (NASDAQ: ENDP)
- BIOLASE Inc. (NASDAQ: BIOL)
- Aeterna Zentaris Inc. (NASDAQ: AEZS)
Finding the best biotech penny stocks to buy is all about understanding the trajectory of the market. With Covid cases increasing in certain parts of the world, many investors are turning their focus back onto the biotech industry.
This is resulting in the increased volume were witnessing and large daily momentum. So, with all of this in mind, which biotech penny stocks are you watching right now?